HCPCS Level II C9163: Injection, talquetamab-tgvs, 0.25 mg

HCPCS Level II code C9163 designates a 0.25 mg unit of talquetamab-tgvs, an injectable biologic product used in specialty oncology care. As a product-specific HCPCS Level II code, C9163 enables itemized billing for drug acquisition and administration in outpatient infusion settings and specialty clinics, supporting claims accuracy and coverage determinations for high-cost therapies. Nationally, precise HCPCS coding for biologics affects reimbursement clarity, prior authorization workflows, and aggregate spending on specialty drugs.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, the typical clinical and site-of-care context, and the payer landscape addressed. The publication summarizes billing and coding considerations, expected places of service, and how payers commonly handle provider submissions for specialty injectable agents. It also outlines the types of benchmarks and policy updates readers can expect to review, including reimbursement coding guidance, coverage policy trends, and implications for claims processing and billing operations.

Data not available in the input is noted where payer-specific rates, taxonomies, ICD-10 mappings, and related codes would normally appear.

Billing Code Overview

HCPCS Level II code C9163 represents Injection, talquetamab-tgvs, 0.25 mg. The service is an injectable biologic medication administration typically used for specialty oncology or hematology therapy consistent with the drug formulation. The typical site of service is outpatient infusion or clinic-based administration, including specialty infusion centers.

Data not available in the input.

Clinical Context

A 62-year-old patient with relapsed/refractory multiple myeloma presents to an outpatient oncology infusion center for administration of C9163 (Injection, talquetamab-tgvs, 0.25 mg). The patient has completed pre-infusion evaluation including review of current medications, laboratory studies (CBC, CMP), and assessment for active infections. The clinical workflow includes verification of the individualized dose based on weight or protocol, pharmacy preparation of the agent in a sterile compounding area, bedside time-out to confirm patient identity and dosing, and administration via subcutaneous or intravenous route per prescribing information (site determined by clinician). During and after administration, nursing monitors for acute infusion-related reactions, cytokine release syndrome, and neurologic symptoms; vital signs are recorded at regular intervals. Post-infusion observation is performed per institutional protocol; patient and caregiver receive education on signs and symptoms requiring immediate medical attention and documentation of the dose, lot number, and administration site is completed in the medical record.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when the work required for preparation or monitoring of `C9163` is substantially greater than typical (rare and well-documented).

Taxonomy Code	Specialty	Notes
`208000000X`	Hematology/Oncology	Medical oncologists and hematologist-oncologists prescribe and oversee administration of talquetamab.
`207RC0000X`	Medical Oncology	Physicians specializing in medical oncology manage systemic therapy and infusion protocols.
`363A00000X`	Oncology Nurse Practitioner	Advanced practice clinicians who manage infusion visits, monitoring, and patient education.
`163W00000X`	Hematology	Hematologists involved in complex blood malignancy management and treatment planning.
`334400000X`	Clinical Pharmacist	Oncology pharmacists who prepare, verify dosing, and compound `C9163` for administration.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C90.00`	Multiple myeloma not having achieved remission	Multiple myeloma is the primary hematologic malignancy for which talquetamab therapy is indicated in relapsed/refractory settings.
`C90.01`	Multiple myeloma in remission	Used when documenting ongoing therapy or maintenance in patients with prior response.
`C90.02`	Multiple myeloma, in relapse	Relevant when talquetamab is administered for relapsed disease.
`D61.9`	Aplastic anemia, unspecified	May be listed as a comorbidity affecting eligibility or monitoring, particularly for cytopenias.
`T80.7XXA`	Infection following infusion, initial encounter	Used if the patient develops an infusion-related infection requiring documentation during the encounter.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug	May be used when IV infusion administration of `C9163` occurs and infusion time fits code definitions.
`96415`	Each additional hour (list separately in addition to primary code)	Used for extended IV infusion monitoring time beyond the initial hour when clinically required.
`96360`	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	May be billed if hydration is provided as a separate supportive measure during the infusion visit.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal antineoplastic	Applicable when `C9163` is administered via subcutaneous route and billing for the administration procedure is needed.
`99024`	Postoperative follow-up visit global period, related to routine postoperative care	May be used for routine follow-up visits related to adverse-event monitoring after administration when applicable.

OpenPayer

Summary & Overview